We are live on ! Find out more
CRBP icon

Corbus Pharmaceuticals
CRBP

80 hedge funds and large institutions have $62.5M invested in Corbus Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 29 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $55.4M → $62.5M (+$7.13M)

7% less funds holding

Funds holding: 86 → 80 (-6)

11.23% less ownership

Funds ownership: 85.29% → 74.06% (-11%)

14% less call options, than puts

Call options by funds: $138K | Put options by funds: $161K

29% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 21

41% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 29

Holders
80
Holders Change
-6
Holders Change %
-6.98%
% of All Funds
1.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
17
Reduced
29
Closed
21
Calls
$138K
Puts
$161K
Net Calls
-$23K
Net Calls Change
+$51K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$598K
2
HP
HealthInvest Partners
Sweden
+$561K
3
Millennium Management
Millennium Management
New York
+$418K
4
Bank of America
Bank of America
North Carolina
+$402K
5
Aberdeen Group
Aberdeen Group
United Kingdom
+$329K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$3.59M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.39M
3
State Street
State Street
Massachusetts
-$1.22M
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$998K
5
Citadel Advisors
Citadel Advisors
Florida
-$676K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$16.4M – – –
O
2
OrbiMed
New York
$8.09M – – –
OCA
3
Octagon Capital Advisors
New York
$7.69M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$4.14M -$527K -72,562 -11%
PM
5
Prosight Management
Texas
$4M +$34.6K +4,757 +0.8%
BlackRock
6
BlackRock
New York
$2.43M -$3.59M -493,653 -58%
EAM
7
Exome Asset Management
New York
$1.91M -$89.9K -12,373 -4%
Comerica Bank
8
Comerica Bank
Texas
$1.38M – – –
AC
9
Armistice Capital
New York
$1.32M -$421K -58,000 -23%
HP
10
HealthInvest Partners
Sweden
$1.21M +$561K +77,278 +79%
Millennium Management
11
Millennium Management
New York
$1.1M +$418K +57,555 +57%
Morgan Stanley
12
Morgan Stanley
New York
$1.1M +$598K +82,388 +108%
Renaissance Technologies
13
Renaissance Technologies
New York
$1.06M -$1.39M -191,661 -56%
Acadian Asset Management
14
Acadian Asset Management
Massachusetts
$1.05M -$275K -37,822 -20%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$926K -$998K -137,423 -51%
TCM
16
Tang Capital Management
California
$880K – – –
Mirae Asset Global ETFs Holdings
17
Mirae Asset Global ETFs Holdings
Hong Kong
$821K -$72.5K -9,987 -8%
UBS Group
18
UBS Group
Switzerland
$634K +$7.26K +999 +1%
PCM
19
Prelude Capital Management
New York
$554K – – –
HS
20
HighVista Strategies
Massachusetts
$520K – – –
Aberdeen Group
21
Aberdeen Group
United Kingdom
$498K +$329K +45,332 +169%
Bank of America
22
Bank of America
North Carolina
$496K +$402K +55,314 +334%
Charles Schwab
23
Charles Schwab
California
$470K -$148K -20,377 -23%
VCIM
24
Velan Capital Investment Management
Georgia
$407K – – –
State Street
25
State Street
Massachusetts
$380K -$1.22M -168,378 -75%
1
2 3 4 5

CRBP Hedge Fund Activity: Q2 2025 in Review

80 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q2 2025, worth a combined $62.5M — up 13% from $55.4M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of CRBP and 15 opened new positions — a net loss of 6 holders — while 29 trimmed existing stakes and 17 added.

The largest buyer was Morgan Stanley, adding an estimated $598K. The largest seller was BlackRock, cutting an estimated $3.59M.

  • 80 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q2 2025, down from 86 in Q1 2025.
  • Funds reported $62.5M of Corbus Pharmaceuticals stock for Q2 2025, up 13% quarter-over-quarter.
  • 15 funds opened new Corbus Pharmaceuticals positions in Q2 2025 and 21 closed out, a net change of -6 holders.
  • The largest Corbus Pharmaceuticals buyer in Q2 2025 was Morgan Stanley, an estimated $598K added.
  • The largest Corbus Pharmaceuticals seller in Q2 2025 was BlackRock, an estimated $3.59M sold.

Based on aggregated 13F filings for Q2 2025.